CGNX vs MLAB: stock comparison and AI forecast
Cognex Corp (CGNX) and Mesa Laboratories Inc /Co/ (MLAB) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
CGNX Cognex Corp
- Price
- $47.78 -27.5% · 6M
- Market Cap
- $8.04B
- P/E Ratio
- 44.2x
- Size
- mid-cap
- AI Forecast
MLAB Mesa Laboratories Inc /Co/
- Price
- $128.25 +20.9% · 6M
- Market Cap
- $718M
- P/E Ratio
- 150.8x
- Size
- small-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Six-month price performance
Closing prices rebased to 100 at the start of the window.
Key facts
- CGNX is 11.2 times larger than MLAB by market capitalization ($8.04B against $718M).
- CGNX trades at 44.2 times trailing earnings, MLAB at 150.8 times.
- Over the last six months MLAB returned +20.9% and CGNX -27.5%.
- CGNX turns 21.5% of its revenue into net income, against 1.9% for MLAB.
- MLAB carries 1.22 times debt per unit of equity, against 0.32 times for CGNX.
- CGNX yields 0.71% in dividends and MLAB 0.49%.
- Both companies share the SEC industry classification Industrial Instruments For Measurement, Display, and Control.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | CGNX | MLAB |
|---|---|---|
| Market Cap | $8.04B | $718M |
| P/E Ratio | 44.24x | 150.77x |
| P/B Ratio | 4.67x | 3.80x |
| Dividend Yield | 0.71% | 0.49% |
| EPS | $1.08 | $0.85 |
| Book Value/Share | $10.23 | $33.73 |
| Revenue/Share | $6.69 | $44.63 |
| FCF/Share | $1.70 | $9.45 |
Profitability & Margins
| Metric | CGNX | MLAB |
|---|---|---|
| ROE | 14.1% | 2.5% |
| ROA | 10.6% | 1.1% |
| ROIC | 13.8% | 6.2% |
| Gross Margin | 69.7% | 64.2% |
| Operating Margin | 25.0% | 9.0% |
| Net Margin | 21.5% | 1.9% |
| EBT Margin | 26.5% | 3.8% |
| Tax Rate | 18.9% | 48.7% |
Financial Health
| Metric | CGNX | MLAB |
|---|---|---|
| Current Ratio | 5.04x | 1.79x |
| Quick Ratio | 4.34x | 1.32x |
| D/E Ratio | 0.32x | 1.22x |
| Financial Leverage | 1.32x | 2.22x |
| Interest Coverage | – | 0.3x |
| Working Capital | $923M | $46M |
Cash Flow
| Metric | CGNX | MLAB |
|---|---|---|
| Operating Cash Flow | $296M | $56M |
| Free Cash Flow | $286M | $53M |
| Capital Spending | -$10M | -$3M |
| OCF Growth YoY | 33.1% | 45.5% |
| FCF Growth YoY | 33.8% | 56.0% |
| FCF/Sales | 25.4% | 21.2% |
| CapEx/Sales | 0.8% | 1.1% |
Operational Efficiency
| Metric | CGNX | MLAB |
|---|---|---|
| Asset Turnover | 0.49x | 0.60x |
| Receivables Turnover | 5.2x | 7.3x |
| Inventory Turnover | 2.1x | 3.3x |
| Fixed Assets Turnover | 14.1x | 8.3x |
| Days Sales Outstanding | 70 days | 50 days |
| Days Inventory | 170 days | 111 days |
| Payables Period | 80 days | 30 days |
| Cash Conversion Cycle | 160 days | 131 days |
Income Statement
| Metric | CGNX | MLAB |
|---|---|---|
| Total Revenue | $1.13B | $250M |
| Operating Income | $281M | $22M |
| Net Income | $242M | $5M |
| R&D Expense | $139M | $20M |
| SG&A Expense | $364M | $118M |
| Cost of Goods Sold | $341M | $89M |
Dividend & Shareholder Information
| Metric | CGNX | MLAB |
|---|---|---|
| Dividends Per Share | $0.34 | $0.63 |
| Payout Ratio | 31.5% | 74.1% |
| Shares Outstanding | 168M | 6M |
| Net Income Growth | 119.7% | – |
| EPS Growth | 96.4% | – |
CGNX vs MLAB: stock comparison and AI forecast
Which is bigger, CGNX or MLAB?
CGNX is 11.2 times larger than MLAB by market capitalization ($8.04B against $718M).
Which is cheaper on earnings, CGNX or MLAB?
CGNX trades at 44.2 times trailing earnings, MLAB at 150.8 times.
Which stock performed better over the last six months, CGNX or MLAB?
Over the last six months MLAB returned +20.9% and CGNX -27.5%.
Which one does Intratio's AI model rank higher, CGNX or MLAB?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.